key: cord-0014102-4i9us8ox
authors: Gorgulla, Christoph; PadmanabhaDas, Krishna; Leigh, Kendra E.; Cespugli, Marco; Fischer, Patrick D.; Wang, Zi-Fu; Tesseyre, Guilhem; Pandita, Shreya; Shnapir, Alec; Calderaio, Anthony; Hutcheson, Colin; Gechev, Minko; Rose, Alexander; Lewis, Noam; Yaffe, Erez; Luxenburg, Roni; Herce, Henry D.; Durmaz, Vedat; Halazonetis, Thanos D.; Fackeldey, Konstantin; Patten, Justin J.; Chuprina, Alexander; Dziuba, Igor; Plekhova, Alla; Moroz, Yurii; Radchenko, Dmytro; Tarkhanova, Olga; Yavnyuk, Irina; Gruber, Christian C.; Yust, Ryan; Payne, Dave; Näär, Anders M.; Namchuk, Mark N.; Davey, Robert A.; Wagner, Gerhard; Kinney, Jamie; Arthanari, Haribabu
title: A Multi-Pronged Approach Targeting SARS-CoV-2 Proteins Using Ultra-Large Virtual Screening
date: 2020-07-24
journal: ChemRxiv
DOI: 10.26434/chemrxiv.12682316
sha: 8573214012bb4557503e3d1597daf745396207e0
doc_id: 14102
cord_uid: 4i9us8ox

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019 novel coronavirus (2019-nCoV), has spread rapidly across the globe, creating an unparalleled global health burden and spurring a deepening economic crisis. As of July 7th, 2020, almost seven months into the outbreak, there are no approved vaccines and few treatments available. Developing drugs that target multiple points in the viral life cycle could serve as a strategy to tackle the current as well as future coronavirus pandemics. Here we leverage the power of our recently developed in silico screening platform, VirtualFlow, to identify inhibitors that target SARS-CoV-2. VirtualFlow is able to efficiently harness the power of computing clusters and cloud-based computing platforms to carry out ultra-large scale virtual screens. In this unprecedented structure-based multi-target virtual screening campaign, we have used VirtualFlow to screen an average of approximately 1 billion molecules against each of 40 different target sites on 17 different potential viral and host targets in the cloud. In addition to targeting the active sites of viral enzymes, we also target critical auxiliary sites such as functionally important protein-protein interaction interfaces. This multi-target approach not only increases the likelihood of finding a potent inhibitor, but could also help identify a collection of anti-coronavirus drugs that would retain efficacy in the face of viral mutation. Drugs belonging to different regimen classes could be combined to develop possible combination therapies, and top hits that bind at highly conserved sites would be potential candidates for further development as coronavirus drugs. Here, we present the top 200 in silico hits for each target site. While in-house experimental validation of some of these compounds is currently underway, we want to make this array of potential inhibitor candidates available to researchers worldwide in consideration of the pressing need for fast-tracked drug development.

At the end of 2019, cases of pneumonia with an initially unknown etiology were identified in Wuhan City, in the Hubei Province of China (1-3). The cause was determined to be a novel coronavirus (CoV) (4), and by early July, 2020, there were over 12 million confirmed cases worldwide (5, 6) of what is now designated SARS-CoV-2 (7). A lineage B Be-tacoronavirus related to severe acute respiratory syndrome CoV (SARS-CoV), SARS-CoV-2 commonly causes fever, cough, myalgia, and/or fatigue (8, 9) . While even half a year later, our clinical knowledge is still developing, in addition to asymptomatic and mild cases, dyspnoea, lymphopenia, and anosmia, with or without dysgeusia, have also been reported as clinical features (8, (10) (11) (12) , and complications can include acute respiratory distress syndrome (ARDS), acute cardiac injury, and secondary infections (8). As of July 8th, 2020, over half a million deaths have been attributed to coronavirus disease 2019 (COVID-19) (5, 6), and the rapid expansion in case number in combination with severe symptoms requiring hospitalization has resulted in unprecedented strain on the global healthcare system.

Coronaviridae is comprised of a family of large positivesense, single-stranded RNA viruses that derive their name from the 'corona' that fringes the virions in electron micrographs (14, 15) . Coronavirus virions are composed of a lipid envelope, decorated with spike (S) protein, which facilitates entry and causes their corona-like appearance (16). Envelope (E) protein, which contributes to virion assembly and viral pathogenesis, as well as membrane (M) protein, which also facilitates virion assembly, are also both embedded in this bilayer (16), and the viral genome, in close association with nucleoprotein (N), is encapsulated within.

To initiate entry, the receptor binding domain of S must engage with its receptor on the surface of its target cell, and several studies have already identified the SARS-CoV recep- tor, angiotensin-converting enzyme 2 (ACE2), as a possible receptor for SARS- 17, 18) . While engagement with the receptor initiates conformational rearrangements in S, the spike protein must also be cleaved at its S2' site as part of the entry process. Unlike the S1/S2 cleavage event, which can occur at any point from viral assembly to entry, S2' cleavage likely only occurs during entry, and involves host proteases at the cell surface, such as transmembrane protease, serine 2 (TMPRSS2), or in endosomes, such as cathepsins (19) . Further conformational rearrangements in S result in membrane fusion, allowing release of the nucleocapsid into the cytoplasm.

As the genome is positive-sense, replication starts with the expression of ORF1a and ORF1ab. The resulting polyproteins (pp1a and pp1ab) are further processed into sixteen non-structural proteins (nsp1-16; see Fig. 1 ) that form, in conjunction with host proteins, membrane-associated replication and transcription complexes (RTCs) (13). The genome is replicated via an intermediate negative-sense copy of the genome and both structural and accessory proteins are expressed from 3'-co-terminal sub-genomic RNAs (20) . Assembly occurs on membranes between the endoplasmic reticulum and the trans-Golgi Network, with the virions budding into vesicular compartments that then fuse with the plasma membrane, releasing their cargo (20) (see Fig. 1 ).

While low-pathogenicity human coronaviruses such as HCoV-229E, HCoV-OC43, HCov-NL63, and HCoV-HKU1 (21) continually circulate and generally cause mild disease, the emergence of in 2002 and Middle East respiratory syndrome CoV (MERS-CoV) (26) (27) (28) in 2012 as the result of zoonotic jumps into the human population (29) demonstrated that coronaviruses could cause serious morbidity and mortality. Their importance made them the subject of extensive research and attractive therapeutic targets. While research is only just beginning on SARS-CoV-2, comparison of the SARS-CoV-2 sequence early in the outbreak to previously identified coronavirus sequences revealed it to be most related to previously isolated bat SARS-like CoVs (1, 2, 30) and comparison to both a bat SARS-like virus (bat SL-CoVZC45) as well as a previous human SARS-CoV isolate (SARS-CoV Tor2) predicted that SARS-CoV-2 likely has a similar genomic organization and expresses similar proteins (2) (see Fig. 1 ). The assignment to the Betacoronavirus genus and in particular the similarity to SARS-CoV, allows us to also draw on a field of already published work to infer promising targets within the SARS-CoV-2 life cycle for small molecule intervention.

Therapeutics against viruses generally fall into two broad categories: i) vaccines, which prime the host immune system to mount a targeted defense against infection by the virus, and ii) other agents with antiviral effects, which include, but are not limited to, small molecule inhibitors, peptides, and biologics. Although effective vaccines have been developed against several viruses, including polio and hepatitis B, there are many viruses for which there is still no vaccine, even after decades of research (31). HIV is the most prominent example of this, but there are also no approved vaccines for any of the human coronaviruses, including SARS-CoV and MERS-CoV.

Other therapeutics with antiviral properties can be broadly divided into two categories: i) drugs that target viral proteins, and ii) drugs that target host proteins, including the viral receptor, cellular proteins essential to the viral life cycle, and components of the immune system. Currently available viral therapeutics include protease inhibitors, reverse transcrip-tase and polymerase inhibitors (both nucleoside analogues and non-nucleoside inhibitors), integrase inhibitors, and viral entry blockers ( Supplementary Fig. 23 ). Although there are no drugs specifically approved by the FDA for SARS-CoV, MERS-CoV or SARS-CoV-2, there have been a number of efforts to target proteins of the viral machinery, including the proteases, helicase and RNA-dependent RNA polymerase (RdRP). A partial list of these published small molecules is shown in Supplementary Table 2 . For instance, Remdesivir, an RdRP inhibitor originally developed for hepatitis C, was previously tested against both SARS-CoV and MERS-CoV. Preliminary studies have suggested that Remdesivir may reduce the time to recovery in SARS-CoV-2 patients; however, this finding needs to be confirmed with larger studies (32).

For every virus, there are targets such as the entry pro-C. Gorgulla | VirtualFlow@COVID-19 ACE2 (gold) in an open conformation bound to the RBD of the spike protein (magenta) and an example compound (light pink) from the virtual screen bound to the spike interaction interface (site 1, around Glu37) (Screen ID: 1). b, The electrostatic surface of the target protein (ACE2) bound to the RBD domain of the spike protein (magenta) and an example compound (light pink). c, An overview of the interactions between the ligand and the receptor structure. d, Receptor residues within 4 Å of the ligand. e, Distribution of the docking scores of the top 100 virtual screening hits.

tein or the viral polymerase, which have direct effects on the ability of the virus to replicate, even under ideal conditions for the virus. There are also other targets that, if inhibited, would reduce the severity of the viral infection often referred to as the viral virulence. Some of these targets may only have an effect when inhibitors are evaluated in the context of a whole organism. For example, several viruses paralyze the host immune system by hijacking or sequestering, key sig-naling proteins, and targeting the viral proteins that mediate this effect would reduce the virulence of the virus. In this study we target an array of SARS-CoV-2 proteins in addition to two human proteins, and we posit that inhibitors, which target proteins that affect the viability and/or the virulence, could synergistically combine for more efficacious combination therapies.

In silico screening methods enable us to identify lead drug candidates for SARS-CoV-2 in an expedited manner, fueled by the availability of high-resolution structures of many of the SARS-CoV-2 proteins. Previous work has shown that the number of compounds screened in a structure-based in silico screen affects the quality of the resulting hits and the potency of the hits derived increases with the number of compounds screened (33). A flurry of recent papers have demonstrated that by using in silico screening to expand the chemical space (screening~100 million compounds), one can identify picomolar-affinity inhibitors (33) (34) (35) . To become capable of screening billions of molecules in a relatively short period (weeks), we recently developed VirtualFlow, an open source computational drug discovery platform (36). Virtu-alFlow, with its linear scaling feature, leverages the power of computing clusters to perform ultra-large scale screens. Here we use the computational power of the Google Cloud Platform (GCP) to identify molecules that could inhibit SARS-CoV-2. We screened over one billion molecules against each of fifteen SARS-CoV-2 proteins and two human proteins, ACE2 and TMPRSS2. For some of the proteins we target multiple functional sites on the protein surface; an approach which provides two distinct advantages: i) the possibility of increasing efficacy using a cocktail approach, and ii) the identification of alternative ways to target the same protein, a ne- cessity when faced with the possibility of resistance mutations. Whenever possible we used recently determined highresolution structures of SARS-Cov-2 proteins in our screens. A complete list of the target proteins along with the models used can be found in 1.

In the realm of in silico screening, the probability of finding a true hit (a hit that is validated experimentally) increases with the number of molecules screened and the accuracy of the chosen structure relative to what exists in solution inside the cell. Small changes in structure or dynamics can be accommodated by flexible docking, but large conformational changes decrease the ability of in silico screening methods to identify potent binders. Large conformational changes can be tackled by ensemble docking methods (molecular dynamics simulations), but the trade-off for these approaches is additional computational time. Targeting protein-protein interactions (PPI) is also challenging for in silico screening. Typically in PPIs the off-rate between the two interacting proteins is slow and the interaction interface is large compared to a small molecule inhibitor. Thus targeting PPIs was approached with the rationale that a small molecule engaging the monomer at the hot spot of the PPI interface can prevent complex formation, driven by an excess concentration of the small molecule. In the absence of a solved dimeric/multimeric structure, we make the assumption that the structure of the monomer is similar to that of the protein in complex, which does not always hold true. For each of the targets that were screened we describe any potential limitations that we anticipate could affect the experimental outcome.

VirtualFlow was used to screen around 1 billion on-demand (synthesizable) compounds from the Enamine REAL library, and around 10 million in-stock compounds from the ZINC 15 library (37) for each targeted site. Both libraries were previously prepared with 'VirtualFlow for Ligand Preparation' (VFLP) (36) . For each virtual screen a single receptor structure was used, and the protein was held rigid. QuickVina W was used to perform a blind docking procedure (38) for the HR1 domain of spike protein, the RNA binding interface of nucleoprotein, the RNA binding site of nsp12, as well as for nsp7 and ORF7a. For all the other docking routines, we used QuickVina 2 (39). Both docking programs are based on AutoDock Vina (40), and the exhaustiveness parameter was set to 1 during all virtual screens. This setting minimizes the search of the conformational space within the docking box and maximizes the computational efficiency.

To conduct VirtualFlow screens we needed to leverage a significant amount of high performance computing (HPC) time and infrastructure in order to complete multiple virtual screens in parallel. For this purpose we have taken advantage of Slurm (https://slurm.schedmd.com), a highly scalable and fault-tolerant workload manager capable of handling multiple jobs in parallel. In addition, the Elastifile Cloud File Storage (ECFS) was used, which is a POSIXcompliant and highly scalable NFS file service mounted to the Slurm cluster compute nodes. ECFS provides a full suite of cloud-native NAS features (including snapshots and multi-zone accessibility). The Google Cloud Platform (GCP, https://cloud.google.com), which combines all of these components, including Google Compute Engine preemptible virtual machines, was used to provide the scale of computation required for the ultra-large virtual screens reported here. Google Cloud Storage was used to durably store the generated data.

We operated within a Google Cloud project that has a single Virtual Private Cloud to provide networking functionality to all the virtual instances. To set up this in-frastructure we leveraged automated deployment tools like Terraform (https://www.terraform.io/) and the Google Cloud Deployment Manager to replicate this architecture across 3 different zones belonging to two different geographic regions. This resulted in three different clusters (Fig. 22 ) that were used for virtual screens against different targets in parallel. This globally distributed architecture allowed us to run hundreds of thousands of cores in parallel, consuming a total of approximately 100 million CPU hours in a total of about 3 weeks for all the virtual screens reported here. The types of nodes used are listed in Table 1 .

The virtual hits resulting from these screens were filtered to remove compounds that have reactive functional groups, a molecular weight greater than 600 daltons, a cLogP greater than 6, or more than 10 hydrogen bond acceptors. A smaller number of non-druglike molecules from the ZINC library were also removed after visual inspection. The top 200 hits for each target site, after the filtering process, are included in the supplementary section. In addition, for each target site, we showcase one of the top hits in the manuscript. This hit was chosen based on consideration of a number of parameters including, but not limited to, docking score, 'druglikeness' (which includes criteria such as Lipinski's rule of five, and the tendency to aggregate as estimated by a fraction of sp3-hybridized carbon atoms between 0.25 and 1), and the presence of PAINS (pan-assay interference compounds) or other potentially toxic moieties. The desire to highlight plausible small molecule-protein interactions that can be accommodated by the docking site was also taken into account when choosing the hit to be depicted. Due to these filtering criteria, it is therefore important to note that although the example hit molecule displayed in each figure is one of the top hits for the represented screen, it is often not the hit with the highest docking score. 

The spike protein forms the highly glycosylated trimeric receptor-binding protein that decorates the virion surface and facilitates entry into the host cell through interaction with its receptor ACE2 (41). Binding of the Receptor Binding Domain (RBD) of S to ACE2 induces large conformational changes in the S2 domain. These changes are followed by processing by host proteases such as TMPRSS2 and cathepsins and result in the formation of a stable six-helix bundle by heptad repeats 1 and 2 (HR1 and HR2) culminating in the fusion of the viral and cellular membranes (8). In order to develop compounds capable of preventing SARS-CoV-2 from entering cells, we focused on the following three targets: a) the interaction interface of the RBD and ACE2, b) the host protease TMPRSS2, and c) the HR2 hydrophobic binding groove of HR1.

Recent studies have revealed molecular details of ACE2 binding with spike-RBD and multiple high-resolution structures of the RBD in complex with ACE2 have been released (PDB: 6M17, 6M0J, 6VW1) (17, 42, 43) . As the primary mediator of host cell attachment, the spike trimer is a clear potential target for thera- peutic intervention, and in order to find an effective inhibitor of viral entry into host cells, we target both ACE2 and the RBD of spike in parallel.

Targeting the spike protein interaction interface on ACE2.

The primary physiological function of the receptor, ACE2, is the maturation of angiotensin, a signalling peptide with cardiovascular regulatory effects (44), making any targeting of the catalytic site of ACE2 unfavourable. Fortunately, the structure of the complex shows that the peptidase (PD) domain of ACE2 has two distinct lobes that are essential for substrate engagement, and while the RBD-ACE2 binding interface includes one of these lobes, it does not obstruct the PD active site (17, 42) (Fig. 2, Supplementary Figs. 1, 2, 3, 4) . This suggests that targeting the RBD interaction interface should not inhibit ACE2 functionality and therefore not affect angiotensin homeostasis. In fact, previous biochemical studies with SARS-CoV have shown that the ACE2 inhibitor MLN-4760, which favors the closed state, does not interfere with S protein binding and vice versa, also arguing for independence of ACE2 function and spike binding (45). We have targeted four different sites on the ACE2 surface. Two of them are located on the spike interaction interface, and would directly disrupt the ACE2-spike interaction ( tered around Glu37), two independent virtual screens were carried out (Screen IDs: 1 and 2): one using an ACE2 structure where no spike protein was bound (PDB: 6m17; Screen ID: 1), and one using an ACE2 structure to which the RBD domain of the spike protein was bound (PDB: 6m18; Screen ID: 2). The difference between these two conformations at the site of binding is relatively small (RMSD: 0.355 Å in the region of the first two N-terminal α-helices), yet significant for structure-based virtual screening. The second site that we targeted on the spike binding interface (Screen ID: 3) is centered around residue Gly354, and was chosen because there is a shallow hydrophobic pocket. The other two sites targeted were two dynamic pockets adjacent to the spike interface on ACE2 potentially capable of accommodating tighter binders (Screen IDs: 4 and 5) (Supplementary Figs. 1, 2) . Compounds bound to the two dynamic pockets could be linked to each other, and the linker, which then would pass over the spike interaction interface, could potentially block the binding of spike protein.

In vitro measurements suggest that SARS-CoV-2 RBD binds to ACE2 with nanomolar affinity (18, 46) . Each peptidase domain of ACE2 can accommodate one RBD and the interaction is mediated through polar interactions. It has previ- ously been shown that the "up" conformation of the RBD is required for receptor binding and that two spike protein trimers can bind to a single ACE2 dimer (17) (Fig. 4) . The RBD itself consists of a core containing an anti-parallel βsheet (β1 to β4 and β7), with three short α-helices and an extended loop. This extended loop engages the α1 helix of the ACE2-PD, and it is the center of this interface on the RBD that we have targeted by virtual screening (Screen ID: 7) (Fig. 4 .

The spike interaction interface on ACE2 is relatively flat and polar, which makes it challenging to identify tightbinding molecules. This difficulty is reflected in the docking scores resulting from the virtual screen of this binding interface: the average docking score of the top 100 virtual hit compounds from this screen was approximately -8 kcal/mol, which is amongst the weakest docking score averages of all the target sites screened (see also Supplementary Fig. 21 ).

The SARS-CoV-2 RBD has significantly higher affinity for ACE2 as compared to that of the SARS-CoV RBD (43, 46) ; however, the full-length spike protein from SARS-CoV-2 shows either similar or weaker affinity for ACE2 (18, 47) when compared to that of the full-length SARS-CoV spike. This contrast in binding affinities between the RBD alone and the full-length spike protein could be a consequence of RBD dynamics where the protein switches between RBD "up" and "down" states as seen in case of 49) . There is limited information available as to whether the SARS-CoV-2 spike favors a 'lying- , where an example compound (light pink) from the virtual screen is bound at the nsp8 (light gold) interface. In the virtual screen, a blind docking was carried out for each screened compound over the entire surrounding helical surface. This helical surface includes large parts of the nsp8 (light gold, cyan) and nsp12 (lavender) binding interfaces (Screen ID: 20) . b, Electrostatic surface of nsp7 to which an example compound (light pink) is bound. Also shown are the protein-protein interaction partners nsp8 (light gold, cyan) and nsp12 (lavender). c, An overview of the interactions between the inhibitor and the nsp7 structure. d, Residues within 4 Å of the inhibitor. e, Distribution of the docking scores of the top 100 virtual screening hits.

down'binding-inactive state or a 'standing up' state capable of receptor binding (18, 46) , and so far no SARS-CoV-2 spike trimer structure with two RBD domains in "up" position has been determined. Furthermore, there is no information on the inherent dynamics within the RBD domain itself, which is where the targeted molecules are expected to bind. This means that it is possible that local protein dynamics could adversely affect binding of some of the hits in ways that the screen is unable to predict.

It should be noted that while targeting the flat surface of the spike-binding interface with ACE2 (Screen IDs 1-3) resulted in compounds with an average binding energy of -8.275 kcal/mol, targeting the dynamic pockets resulted in hits with the potential for higher affinity binding. The binding energy of hits in the dynamic pockets was as high as -10.3 kcal/mol. Experimental validation of these hits would be required to confirm an affinity difference.

TMPRSS2. The essential priming of S during entry can be executed by the host serine protease TMPRSS2 in the case of SARS-CoV-2, making it a potential therapeutic target. In addition, recent research has shown that the TMPRSS2 inhibtor, camostat mesylate, can block viral entry in cell-based assays (41). Effective inhibition of TMPRSS2 could have multiple applications, since processing of ACE2 by TM-PRSS2 has also been shown to be crucial for activation of S in SARS-CoV (50). Although TMPRSS2 has been shown to activate protease-activated receptor 2 (PAR-2) and hepatocyte growth factor (HGF), giving it possible roles in tumor metastasis and epithelial-mesenchymal transition (51), the exact physiological function of this protein is still unknown. TMPRSS2-deficient mice showed no significant phenotypic changes (52), and thus TMPRSS2 is considered to be dispensable for normal cellular function, making a TMPRSS2specific inhibitor less likely to have side effects.

TMPRSS2 itself contains a cytoplasmic domain, a transmembrane domain, an extracellular low-density-lipoproteinreceptor (LDLR) domain, a scavenger-receptor cysteine-rich (SRCR) domain and a C-terminal serine protease domain. The TMPRSS2 precursor consists of 492 amino acids and auto-catalytic cleavage at Arg255 generates the active protease (53). As a chymotrypsinogen-like protease, TMPRSS2 contains a catalytic triad consisting of residues His296, Asp345 and Ser441. As there are currently no experimental structures available for TMPRSS2, we used a homology model from SWISS-MODEL that is based on the human serine protease hepsin (PDB: 5CE1.1A), which shares 33.82% sequence identity with TMPRSS2. Approximately 1 billion compounds were screened against the active site of this homology model (Fig. 3) .

Since a homology model was used to screen for inhibitors, success would depend on the how closely the model represents the actual structure. The active site of TMPRSS2 is well conserved when compared to the template and other serine proteases, and contains Ser, His and Asp residues. The residues around the binding pocket are also well conserved, making it very likely that the predicted structure is sufficiently accurate in the region around the active site binding pocket, which is what we targeted (Screen ID: 6). Our top 10 hits had an average binding energy of -11.35 kcal/mol, which should ideally result in nanomolar inhibitors. It must be noted that experiments with the TMPRSS2 inhibitor camostst mesylate in cultured cells showed that complete inhibition of viral entry is achieved only in conjunction with an inhibitor of CatB/L (E-64d) (41); however, the impact of this residual priming of S by CatB/L on viral pathogenesis in vivo has yet to be well studied.

HR1-HR2 interface. While the S1 subunit of the spike protein is crucial for host cell attachment, the S2 subunit plays an essential role in membrane fusion and subsequent entry into the host cell. Heptad repeats HR1 (residues 912-984) and HR2 (residues 1163-1213) in S2 interact to form the classic six-helix bundle (6-HB) of a class I entry protein (54, 55).

The HR domains of the spike protein and their mode of interaction are known to be highly conserved across CoVs, making them an attractive target for the development of pancoronavirus fusion inhibitors (56).

The central trimeric coiled-coil of HR1 has three hydrophobic grooves (Fig. 5 ) that are proposed to be potential drug binding sites for inhibition of viral fusion. The recent crystal structure of HR1-L6-HR2 (PDB: 6LXT) displays a 6-HB structure with the HR1 domains forming a parallel trimeric coiled-coil around the anti-parallel HR2 domain. The hydrophobic groove formed by the HR1 helices is also the binding interface for the HR2 domain (57). The hydrophobic interaction between HR1 and HR2 is in the area of the fusion core, and previous studies have shown that both HR1 and HR2 components of this fusion core interface could be effectively targeted using complementary peptides in SARS-CoV-2 and MERS-CoV (54, 58).

We performed a blind docking using QuickVina W against the entire surface of the trimeric alpha helix (Screen ID: 8) (Fig. 4) . The resulting hits could not only potentially have high inhibitory activity against multiples CoVs, but could also have both prophylactic and therapeutic applications as was seen previously in the case of a peptide inhibitor (59).

Ligands binding to each of the three different hydrophobic grooves could be identified and linked together in order to enhance the overall affinity and thereby increase the potency.

Once coronavirus enters the cell, translation of the replicase gene gives rise to two large polyproteins, PP1a and PP1ab, composed of nsp1-11 and nsp1-16, respectively. M pro and PL pro cleave these polyproteins into individual nsps, which facilitate genomic replication and transcription of subgenomic RNAs. In order to develop small molecules capa- ble of inhibiting replication we targeted the following five proteins and protein complexes, selected based on the availability of high-resolution structures and available information about their molecular mechanisms: a) the coronavirus primary protease (M pro , nsp5), b) the papain-like protease (PL pro , nsp3), c) the RNA-replication complex, composed of the RdRp (nsp12) and its co-factors nsp7 and nsp8, d) the helicase (nsp13), and e) the ssRNA-binding protein nsp9.

M pro (3CL pro ). M pro (3CL pro ), the main protease of coronavirus, cleaves PP1a and PP1ab into many of their constituent nsps (11 cleavage sites in PP1ab). The inhibition of M pro would not only inhibit the protease itself, but also hinder downstream processes by preventing the production of key viral proteins through inhibition of their proteolytic processing. Proteolytic cleavage by M pro via the catalytic dyad (Cys-His) occurs at the P1 glutamine residue in the cleavage motif (60). Dimerization is thought to create a substrate binding cleft (61), and simulations suggest that only one monomer is active at a time (62). M pro is highly conserved not only in SARS-CoV and SARS-CoV-2, but also among other viruses of the Nidovirales order (enveloped positive-sense singlestranded RNA viruses that produce nested 3'-co-terminal genomic RNAs), making it a potential target for the development of antiviral drugs with broad efficacy (63). Using the same strategies that allowed crystallization of SARS-CoV M pro (64), several groups determined the threedimensional structure of SARS-CoV-2 M pro in its apo form or bound to various inhibitors (65-71). These structures revealed that the N-terminus of SARS-CoV-2 M pro contains two domains (domain I, residues 10-99; domain II, residues 100-184) that adopt a chymotrypsin-like fold, whereas the M pro C-terminal Domain III (residues 201-303) is composed of five α-helices and is responsible for the intermolecular interactions critical for the dimerization. The protease active site of the picornavirus 3C-protease-like domain is located at the cleft formed between domains I and II and contains a Cys145-His41 catalytic dyad. A total of five protein segments comprised of residues 25-27 and 44-50 from domain I and residues 140-143, 165-168 and 188-190 from domain II form the walls of the active site ( Supplementary Fig. 20a ).

The M pro active site seems to show significant conformational flexibility (72). Comparison of three apo structures and five structures in complex with inhibitors reveals changes in the conformation and position of the Gln189-containing loop and the short Ser46-containing α-helix ( Supplementary  Fig. 20b) . Specifically, the cleft between domains I and II is narrower in the apo structures than in the structures of M pro bound to inhibitors, consistent with an induced-fit or confor- mational selection upon ligand binding.

Given the plasticity of the active site, we used two different conformations of M pro for in silico screening (Screen IDs: 16 and 17) (Fig. 6, Supplementary Fig. 5 ). The first conformation corresponded to the structure of M pro bound to the peptide-like inhibitor N3 (66) . For this search, the protein model used was exactly the protein structure reported in the PDB file, after removal of all water molecules and bound ligands (Screen ID: 16) ( Supplementary Fig. 20c ). The second conformation corresponded to the structure of M pro bound to inhibitor 11b, an inhibitor with peptide-like features (67). However, the model used for screening differed slightly from the conformation reported in the PDB file. In the crystal structure, the side chain of Met49 projects into the active site and thus would potentially interfere with compound docking. To avoid this, a different Met49 side chain rotamer was used that did not project as much into the active site. This change resulted in steric clashes with the side chain of Ser46, for which selection of a different side chain rotamer resolved these incompatibilities. Finally, a rotamer for Cys145 was selected that results in its side chain pointing towards the core of the protein. This rotamer was selected to allow the possible docking of compounds that could form covalent bonds with the Cys145 thiol group (Supplementary Fig. 20d) . The two conformations screened, hereafter referred to as M pro -N3 (Screen ID: 16) and M pro -11b* (Screen ID: 17), respectively, identified compounds that docked with high binding energies ( Supplementary Fig. 20) . Interestingly, the M pro -11b* conformation resulted in predicted binding free energies that were approximately 0.5 kcal/mol lower than the binding free energies (docking scores) obtained from screening the M pro -N3 conformation. Moreover, amongst the top 1000 hits identified by screening each of the two conformations (with the application of the standard filtering criteria of logP less than 6, molecular weight less than 600 daltons, and no reactive groups), only 12 hits overlapped. These results illustrate how screening closely related protein conformations can lead to the identification of a diverse set of docked compounds and this may be a generalizable strategy for in silico screening of proteins that exhibit conformational flexibility, such as SARS-CoV-2 M pro (72).

Since the dimerization of M pro is known to be essential for its catalytic activity (73-75), we also targeted the dimerization interface, which relies primarily on the α1 helix of the C-terminal domain (Screen ID: 18) . Previous studies have shown that the inter-conversion of M pro from monomer to dimer is mediated by an order-to-disorder transition of α5, and this aids domain swapping without exposure of the protein's hydrophobic core (76) . Since the C-terminal region of M pro is fully conserved between SARS-CoV and SARS- CoV-2, we used an NMR ensemble of the SARS-CoV M pro C-terminal domain (PDB: 2LIZ) to build a hybrid model of a disordered C-terminus. We subsequently used this model and screened against the attachment site of the α5 helix (Screen ID: 19) . Potential binders at this position would be expected to trap the protein in its inactive monomeric form.

PL pro . SARS-CoV-2 nsp3 is a multi-domain protein containing an N-terminal ubiquitin-like fold, a glutamic-acid-rich acidic domain, a phosphatase domain, a SARS unique domain (SUD), a catalytically active PL pro domain, a marker domain (G2M), and two transmembrane domains (77). In addition to the protease activity, PL pro also possesses deubiqui-tination and de-ISGylation activity that aids in the disruption of the interferon regulatory factor 3 (IRF3) pathway and host innate immune responses (78). The central α-helical "thumb" domain of PL pro harbors the catalytic Cys112, while the Cterminal domain is mostly β-sheet and includes the "palm" domain, which harbors the other two residues of the catalytic triad, His275 and Asp287, and the "fingers", which coordinate a Zn 2+ ion (PDB: 6W9C). PL pro also has two blocking loops (BL1 and BL2) targeting which will prevent the substrate from entering the active site.

Comparison of the crystal structures of PL pro in its unbound and peptide inhibitor-bound states (PDB: 6w9c and 6wx4, respectively) revealed conformational changes in both the "finger" domain as well as the BL2 loop. We therefore targeted the active site in unliganded and the bound states, which correspond to the open and closed conformations the active site (Screen IDs: 12 and 15 respectively) Fig. 7(Fig.  9 ).In addition to this, we also targeted the accessory cleft leading to the active site which would prevent the substrate access to the active site (Screen ID: 13). (Supplementary Fig. 6 ). In addition to the three sites that are described here, the ubiquitin contact site in Pl pro which is critical for the deubiquitination and deISGylation functions was also targeted, and is described in detail elsewhere in this manuscript.

Replication complex: nsp7, 8 and 12. nsp12, 7, and 8 form a minimal 160-kDa complex capable of nucleotide polymerization with additional nsps playing important roles in RNA modification (79, 80) . nsp12 encodes for the RNAdependent RNA polymerase (RdRp) while nsp7 and nsp8 are cofactors, which may form a hexadecameric supercomplex (81) . When compared to the SARS-CoV replicase, key functional residues are found to be fully conserved in SARS-CoV-2; however, there are substitutions on the surface of the complex. The RNA polymerase domain of nsp12 has an Nterminal nidovirus-unique N-terminal extension (NiRAN) in addition to the "finger", "palm", and "thumb" domains com- mon to polymerases (82) (Figs. 15, 16, 17, Supplementary Figs. 12, 13) . The seven catalytic motifs found in other known viral polymerases, and which are involved in template and nucleotide binding and catalysis, are also well conserved in the SARS-CoV-2 polymerase (82, 83).

The SARS-CoV-2 RNA synthesis machinery is governed largely by a number of protein-protein interactions, and this provides us with an opportunity to target these interfaces using small molecules. The C-terminal head domain of nsp8 wraps around the nsp7 helical bundle, forming a hexadecameric complex. nsp8 has been suggested to possess RdRp activity of its own, and produce the primers utilized by the primer-dependent nsp12 RdRp. This nsp12 activity requires the formation of a large oligomeric complex that brings active site residues into proximity with each other (84, 85) . A previously determined crystal structure (PDB: 2AHM) shows nsp7 and nsp8 capable of interacting in at least two ways: i) residues on the C-terminal end of the nsp8 shaft form a hydrophobic core with residues in helix 1 of nsp7; and ii) helix 1 and the short helix of nsp7 interact with one of the helices of the nsp8 head domain (Fig. 12 ). The heterodimer formed by nsp7-nsp8 interaction binds to nsp12 on the polymerase "thumb" domain facing the NTP entry channel, thus placing the nsp12 polymerase "index finger" loop between nsp7-nsp8 and the polymerase "thumb" domain ( Fig. 13 ). In addition to this interaction, a second nsp8 monomer binds to the nsp12 interface domain in the vicinity of Leu117. We targeted the nsp12 binding interface on nsp8 (Screen ID: 22) (Fig. 9) , the nsp7 binding interface on nsp8 (Screen ID: 21) (Fig. 13) , the entire alpha-helical surface of nsp7 which includes the nsp8 and nsp12 binding interfaces (Screen ID: 20) (Fig. 12) , the nsp8 binding interface on nsp12 (Screen ID: 31) (Fig. 15 ), two sites in the RNA binding region on nsp12 (Screen IDs: 28 and 29) (Fig. 16, Supplementary Fig. 12) , and the nsp7 binding interface on nsp12 (Screen ID: 32) ( Supplementary  Fig. 13 ).

The nsp7 binding interface on nsp12 is relatively shallow, and the RNA binding sites are as well, but to a lesser degree. One of the principal challenges of targeting an RNA binding interface is the strong avidity effect, frequently in the nanomolar range, that restricts the ability of ligands from displacing RNA. Moreover, biological processes involving RNA-protein interactions are also known to often be dynamics-dependent. The average binding free energies of the top 100 hits from the screens of the RNA binding interfaces of nsp12 (Screen IDs: 28 and 29) were -11.8 and -10.2 kcal/mol, respectively. nsp13: helicase. nsp13, which is one of the few proteins that is fully conserved in SARS-CoV and SARS-CoV-2, has known activity as an RNA helicase, NTPase, dNTPase, RT-Even though we used a homology model, this model is expected to be reliable because the helicase of SARS-CoV-2 shares 99.8% sequence identity with the template used (PDB:6JYT, structure of SARS-CoV nsp13). However there are currently no helicase structures available for CoVs with nucleic acid bound, and this uncertainty about the residues actually participating in RNA binding is a confounding factor while screening against this target. According to previously reported hydrogen-deuterium exchange experiments, the 1A and 2A domains undergo a series of conformational changes during nucleotide binding and ATP hydrolysis (88), and this inherent flexibility could impact the plasticity of the screened binding pockets and therefore the reliability of the model screened. Our two virtual screens for the RNA binding interface (Screen IDs: 34 and 35) resulted in top 100 hits with an average binding free energy of -10.225 and -10.704 kcal/mol, respectively, and the screen for the active site inhibitors (Screen ID: 33) resulted in an average binding energy of -10.224 kcal/mol. nsp9: ssRNA binding protein. nsp9 is known to colocalize with nsp7, nsp8 and nsp10 within the replication complex and is presumed to play a role in RNA replication (89) . A study on SARS-CoV nsp9 has shown that nsp9 is an ssRNA-binding protein indispensable for viral RNA replication in mouse models (90). There are several high resolution crystal structures available for nsp9 (91, 92) , including those of the protein from SARS-CoV-2 (PDB: 6W4B, 6W9Q). Since dimerization has been found to be essential for viral replication (93), we chose to target the dimerization interface as a method of inhibiting viral replication.

nsp9 contains seven antiparallel β-strands and an α-helix ( Supplementary Fig. 8 ). The dimer interface is formed mainly by the parallel association of the C-terminal α-helices (Fig. 11) , and this surface, in particular the GXXXG motif, was targeted using VirtualFlow (Screen ID: 23). We also targeted a shallow cavity around Phe75 that partially overlaps with the first targeted site centered on the α-helix (Screen ID: 24). This second site interacts with the NTD of the other nsp9 monomer, and is more concave in shape than the first site, making it more pocket-like. The average docking scores of the top 100 compounds of the second targeted site is -9.2 kcal/mol, making it slightly stronger than the first site with an average of -9.1 kcal/mol (see also Supplementary Fig. 21 ).

The C-terminal α-helix, which is responsible for dimerization has a high hydrophobic amino acid content, and the dimer is mainly facilitated by hydrophobic interactions. Targeting this region may lead to hits that are hydrophobic and interacting in a non-specific manner, something that would need to be addressed during follow-up experimental validation. Targeting the dimerization interface is made more difficult because it is not clear if the monomer alone adopts a different conformational state compared to the structure in dimeric form, which was targeted here. The interface is relatively hydrophobic and lacks deep pockets, making it challenging to find specific tight binding compounds.

Initial studies on SARS-CoV-2 in ex-vivo systems and on clinical samples suggest that infection produces lower levels of interferon and differential cytokine/chemokine profiles, even when compared to the closely related 95) . This suggests that SARS-CoV-2 is able to escape, at least initial, host immune surveillance, and when combined with robust early replication (95, 96), allows the virus to establish a strong foothold in the host, forcing the immune system play catch-up. In light of this, targeting SARS-CoV-2 immune evasion factors, particularly in combination with other inhibitors, could have clinical benefits.

Coronaviruses have an RNA genome and during its life cycle produce RNA species normally absent in the host cell's cytoplasm, such as dsRNA and RNA with a 5'-triphosphate. Sensing of RNA intermediates such as these is one way in which the host cell can detect viral infection and initiate an antiviral immune program (97). An effective way in which coronaviruses avoid recognition by these intrinsic immune sensors is by using methyl transferases to add a capstructure to viral RNA in order to mimic the cell's own mRNA (98) . Coronaviruses also encode an endoribonuclease, which prevents the accumulation of viral RNA that could activate dsRNA sensors in the cell (99). The deubiquitination and deISGylation activities of PL pro further interfere with the host antiviral response by antagonizing the induction of type I interferon (IFN) pathways (100). With the goal of preventing coronavirus from being able to evade or subvert host defense mechanisms, we targeted the following four proteins: a) the guanine-N7 methyltransferase/ExoN (nsp10-14) complex, b) the 2'-O-ribose methyltransferase (nsp16), c) the uridylatespecific endoribonuclease (NendoU/nsp15), and d) the deubiquitination and deISGylation activities of PL pro .

Guanine-N7 methyltransferase/ExoN (nsp10-14 complex). nsp14 is critical for viral replication and transcription, as it plays dual roles in proofreading and mRNA capping (101-103). Disruption of nsp14 exonuclease activity (104) has been shown to result in increased sensitivity of the virus to Ribavirin (RBV) and 5-fluorouracil (5-FU) (81), demonstrating the importance of this 3'-mismatched dsRNA excision activity (105). The ExoN activity relies on heterodimer formation of nsp14 with nsp10, and disruption of this interaction has been demonstrated to result in lowered replication fidelity (106). Unlike many other RNA viruses, coronaviruses have a low mutation rate by virtue of this ExoN activity, which supported the expansion of coronavirus genomes (107) and is directly linked to its virulence (108) . Previous work with SARS-CoV has suggested that the limited efficacy of RBV in vivo may be due to excision by this ExoN activity (109), and work in MHV has shown that a mutant strain lacking ExoN activity was more sensitive to Remdesivir (110) . These data suggest that use of a nucleoside analogue might be more effective if combined with an ExoN inhibitor (107). nsp14 also functions as a SAMdependent guanine-N7 methyltrasferase (N7-MTase) (103). Mutation studies in a replicon system have shown that this N7-MTase activity is critical for viral replication and transcription (103). This activity is used to add a cap 0 structure at the 5' end of viral mRNA, thus mimicking a defining structural feature of host mRNAs and assisting translation (111) as well as in in evading host defenses (112) . For nsp14 we targeted three sites, i) targeted the active site of the ExoN domain (Screen ID: 37) (Fig. 22) ii) the active site on the methyltransferase domain (Screen ID: 38)16 and iii) the PPI interface with nsp10 (Screen ID: 36)15.

In the bimodular nsp14, the N-terminal domain of nsp14 up to Lys288 interacts solely with nsp10 and forms the ExoN domain, whereas the C-terminal domain possess the N7-MTase activity. The ExoN domain is comprised of a twisted parallel β-sheet made up of five β-strands and are bordered by α-helices on both the sides (Fig. 22, Supplementary Figs. 15, 16) (113). The N7-MTase domain of nsp14 is made up of five β-strands, and the ligand binding pocket is situated between the β1 and β2 sheets (113). We screened against three distinct sites on nsp14: the nsp10 binding interface (Screen ID: 36)( Supplementary Fig. 15 ), the active site of the ExoN domain (Screen ID: 37) ( Supplementary Fig. 16 ), and the active site of the N7-MTase domain (Screen ID: 38) (Fig. 10) . As there are not yet any experimental structures available for the SARS-CoV-2 nsp10-14 complex, we used a high confidence homology model constructed from the SARS-CoV ExoN/N7-MTase structure (PDB:5C8U) for our docking experiments. It should be noted that while nsp10 is 97% conserved between the two viruses, nsp14 is only 73% identical.

The nsp10 interaction site on nsp14 has a shallow pocket that is fairly hydrophobic, resulting in relatively high docking scores for the top scoring compounds. However, due to the sparsity of polar atoms at this site, it is challenging to find compounds that form sufficient electrostatic interactions to provide the compounds with specificity. By comparison, the ExoN active site is more polar in nature, and forms a wide shallow pocket. This should lead to a larger proportion of the hits that bind with high specificity, but the absence of a deep pocket would affect the binding affinity. The third target site, the active site of the N7-MTase domain of nsp14, also harbors a relatively large hydrophobic cavity, but with with polar elements. The suitability of each of these nsp14 pockets to accommodate ligands is reflected in their mean docking scores (for the top 100 hits for each target site): -10.4 kcal/mol for the PPI site, -13.4 kcal/mol for the N7-MTase active site, and -9.8 kcal/mol for the ExoN active site.

2'-O-ribose methyltransferase (nsp16). RNA cap modifications are known to play a role in the host cell's identification of self-RNA. For example, foreign RNA which lacks 2'-O methylation is inhibited by IFIT1 (114) . Pathogenic viruses such as coronaviruses that replicate in the cytoplasm have developed tactics to escape recognition by the host innate immune system. One such coronaviral mechanism is 2'-O-methyl capping of viral RNA by the nsp10-nsp16 complex. nsp16 is an m 7 GpppA-specific, SAM-dependent, 2'-O-MTase that must form a complex with nsp10 for its function (115, 116) . We therefore targeted the nsp10 binding interface on nsp16 ( Supplementary Fig. 17 ).

nsp16 has a catalytic core comprised of a β-sheet flanked by eleven α-helices (Fig. 23, Supplementary Fig. 17 ). nsp10 has a small antiparallel β-sheet sandwiched between several α-helices and a large loop. The interaction surface of nsp10 with nsp16 is a mixture of hydrophobic, polar, and positively charged, and helps in the stabilization of the SAM binding site (PDB:6W75). However, since the interface is relatively flat and polar, it is rather challenging to find small molecules that bind with sufficient strength.

Earlier structural studies showed that stabilization of the SAM-binding pocket by the nsp10-16 interaction also expands the RNA-binding pocket of nsp16 (117), and short peptides derived from the interaction interface have been shown to inhibit 2'-O-methyltransferase activity of the nsp10-16 complex (118). Therefore, in addition to targeting the in-teraction interface of nsp10 and nsp16 (Screen ID: 40), we also targeted the putative SAM binding site (Screen ID: 41, Supplementary Fig. 17 ). SAM binding has been shown to be essential for both nsp10-16 complex formation as well its catalytic function in another highly pathogenic coronavirus, .

Uridylate-specific endoribonuclease. nsp15 is a uridylate-specific endoribonuclease (NendoU) carrying a C-terminal catalytic EndoU domain that has been described as having various roles in immune evasion in different coronviruses. A recent study in mouse hepatitis virus (MHV), a murine coronavirus, showed that nsp15 was critical for evasion from host dsRNA sensors in macrophages (120), and in porcine deltacoronavirus, nsp15 was found to inhibit IFN-β production (121). The SARS-CoV-2 nsp15 monomer is composed of three distinct domains: a) an N-terminal domain containing an antiparallel β-sheet and two α-helices, b) a central domain composed of 10 β-strands and three short helices , and c) a C-terminal NendoU domain composed of two antiparallel β-sheets and five α-helices (PDB:6VWW) (122). The SARS-CoV-2 nsp15 monomer is capable of forming dimeric, trimeric, and double-ring hexameric assemblies. It has been shown that the hexameric form is essential for enzymatic activity and that the hexamer is stabilized by interactions of the N-terminal oligomerization domain (123). The NendoU active site itself is located in a groove between the two β-sheets, and conserved, crucial residues have been previously identified: His235, His250, Lys290, Thr341, Tyr343, and Ser294. With the aim of disrupting the endoribonuclease activity of nsp15, the active site was targeted in an in silico screen (Screen ID: 39, Fig. 20) .

Deubiquitination and DeISGylation activities of PL pro . PL pro (nsp3) cleaves at a consensus cleavage motif, LXGG, which is also the consensus sequence recognized by cellular deubiquitinating enzymes (DUBs). Coronaviruses attenuate the host anti-viral response by deubiquinating key components of the interferon-mediated immune response. While PL pro uses its catalytic site for its deubiquitination function, ubiquitin itself makes contacts with the "palm" and "fingers" regions of PL pro (124). This protein-protein interface is well conserved in SARS-CoV-2 and could be targeted in order to inhibit the deubiquitination function of nsp3. SARS-CoV has also been shown to possess deISGylation activity, in which ISG-15, a protein modifier consisting of two tandem ubiquitin-like domains involved in modulating the innate immune response, is cleaved (125). We therefore targeted the proximal 'S1' Ub contact site (S1Ub) of the "palm" of nsp3 (Fig. 8) , inhibition of which could effectively block both the deubiquitination as well as deISGylation activities of PL pro (Screen ID: 14) . The binding interface is moderately hydrophobic and concave, making it an attractive drug target. nsp3 macrodomain. The macrodomain, sometimes also called the X domain, is a highly conserved region of~180 amino acids that binds to ADP ribose (126) and which has been shown to be dispensable in RNA replication, at least in the context of an RNA replicon (127). However, it has been shown to have possible roles in evading host innate immune response (128, 129) . Viral macrodomains are known to have two major enzymatic activities: i) ADP-ribose-1'' phosphatase activity where the phosphate is removed from ADPribose-1'' phosophate, and ii) ADP-ribose hydrolase activity where ADP ribose is removed from mono-or poly-ADPribosylated proteins (130) .

Previous biochemical studies showed that the nsp3 macrodomain is responsible for processing of ADP-ribose-1''-phosphate, which is a byproduct of pre-tRNA splicing (131, 132) . This phosphatase activity has been found to be specific for ADP-ribose-1''-phosphate, however the turnover was found to be very low (133, 134) with a kcat of 1.7 to 20 min -1 ), making it unlikely that this activity has a strong direct effect on viral virulence.

ADP-ribosylation is a critical post-translational modification catalyzed mainly by poly (ADP-ribose) polymerases (PARPs) in which ADP-ribose is added to a protein (135). Several PARPs are known to be interferon-stimulated genes (ISGs), and some PARPS have been shown to have antiviral activities. Studies in SARS-CoV and MERS-CoV have shown that these viruses were less virulent in the absence of the macrodomain and that this directly associated with changes in pro-inflammatory cytokine expression (136, 137) . Additional studies in HCoV-299E and SARS-CoV suggested that the nsp3 macrodomain may mediate the resistance to antiviral interferon responses (128). Mutation of the macrodomain in SARS-CoV also induced a strong interferon and inflammatory cytokine response in the lungs of infected mice (136). However, the exact mechanism linking the hydrolase/phosphatase activity of nsp3 and the observed cytokine production is unknown. The fact that a) the macrodomain participates in reversing antiviral ADP ribosylation (130, 138) , and b) mutation of a highly conserved asparagine residue abolishes phosphatase and hydrolase activites and mitigates viral virulence (136, 139) , suggests that targeting the ADP-ribose binding pocket could be an effective therapeutic strategy, particularly in combination with other targets. We observed two different conformations for the active site in the same X-ray structure, which indicated protein dynamics that could affect the ability of the docking to accurately recapitulate the solution-state structure. We therefore targeted both conformations of the active site of the macrodomain: one in which the active site is more closed (Screen ID: 11; Fig. 10 ), and a second conformation in which the active site is more open (Screen ID: 12; Supplementary  Fig. 7) . It is also important to note that the active site itself is very hydrophobic, which increases the risk that the resulting hits could bind non-specifically to membranes and hydrophobic pockets in other proteins, and this should be accounted for in any follow-up screening.

ORF7a. ORF7a is a non-essential accessory protein with a transmembrane helix at the C-terminus that is known to localize to the ER, Golgi, and cell surface (140, 141) . The assembly of ORF7a into viral particles suggests that the protein is important in the viral replication cycle, and that it might have a function early on in the infection (142). In SARS-CoV, ORF7a is known to interact with a 'host restriction factor', bone marrow stromal antigen 2 (BST-2) (141), which inhibits viral replication by preventing virus budding from the plasma membrane (143). ORF7a, which otherwise localizes to the Golgi, has also been shown to localize to the ER when co-expressed with BST-2. Moreover, ORF7a interferes with the glycosyslation of BST-2, which is essential for its tethering/restriction function (141) . There are also indications that ORF7a may play a role in virus-induced apoptosis (144); however, further studies are needed to understand the mechanism of this role.

Structurally, ORF7a has an N-terminal signal peptide, an 80 amino-acid long luminal domain, a transmembrane domain, and a short C-terminal cytoplasmic tail (140). In the recent experimental structure of the SARS-COV-2 ORF7a (PDB:6W37, (145)), the luminal domain displays structural characteristics similar to that of previously published ORF7a structures, and is composed of a seven-stranded β-sandwich ( Fig. 21) with topological similarities to the Ig super family. Interestingly, a very recent genomic analysis of a sample picked up during sentinel surveillance in the state of Arizona in the USA revealed a 27 amino-acid in-frame deletion in ORF7a, in a region pertaining to the N-terminal signal peptide (146). The functional consequences of this deletion, however, are not known. Since the molecular mechanism of the ORF7a interaction is largely unknown, we pursued a blind docking strategy for this protein that covers the complete protein structure (Screen ID: 9) (Fig. 21) . Interestingly, almost all top scoring compounds bound at a shallow cavity around Phe46, while a few bound to the opposite side near Leu31.

During an experimental validation phase, it will need to be verified whether these hits can inhibit the interaction of ORF7a with small glutamine-rich tetratricopeptide repeat-containing protein (SGT)(147) or lymphocyte associated antigen 1 (LFA-1) (148), both of which are thought to play a role in virus-host interactions and host cell-cycle modulation. The presence of ORF7a on the viral surface means that LFA-1 could possibly be a viral attachment factor in leucocytes (142, 148); however there is currently insufficient data available about the possible residues and the structural dynamics that would be involved in this interaction. Moreover, the rather flat surface of ORF7a devoid of pockets or clefts make it challenging for finding small molecules with selective and potent binding.

As the viral lifecycle progresses, the structural proteins (S, E, M) are also expressed. These structural proteins are initially inserted into the endoplasmic reticulum (ER), but transition to the ER-Golgi intermediate compartment (ERGIC) where they aid the formation of mature virions (149). Nucleocapsid protein (N) forms large oligomeric complexes with the replicated viral genome. The resulting ribonucleoprotein (RNP) complexes associate with M, facilitating packaging of the genome into a complete virion assembly. Since there is very little structural information available about M and E, our efforts to find compounds that can disrupt the viral assembly and packaging are centered on the nucleocapsid protein.

The nucleocapsidprotein (N) packages the viral RNA into a helically ordered RNP (150) and plays a critical role in virion assembly by interacting with M. N is also known to play key roles in the regulation of viral RNA synthesis and modification of the host cell metabolism (151). The structure of N consists of an Nterminal RNA-binding domain (NTD, Fig. 24 , Supplementary Fig. 18 ), an intrinsically disordered SR-rich linker, and a C-terminal dimerization domain (CTD, Fig. 25, Supplementary Fig. 19 ). The published crystal structure of the RNA-binding domain reveals a β-sheet core sandwiched between two loops. The β-sheet core has five antiparallel βstrands plus a short helix, and a longer β-hairpin between strands β2 and β5 (PDB:6M3M (152). The central β-strands of the β-sheet core contain a purine/pyramidine monophosphate binding site, and this ribonucleotide binding mechanism is essential for virulence, making it an attractive drug docking site (153). The NTD is also expected to interact with the CTD during RNA packaging. We have therefore targeted two minimally overlapping regions of the NTD, which together cover the entire surface of the NTD (screen IDs: 42 and 43) (Fig. 24, Supplementary Fig. 18 ). The first site includes the ribonucleotide-binding site reported in (153).

The CTD of N aids dimerization of the protein as well as RNA binding. The monomer consists of eight α-helices and a β-hairpin. The dimerization interface itself is composed of three helices (α5, α6 and α7) and one β-hairpin from each monomer, and involves a combination of hydrogen bonds and hydrophobic interactions, which result in a very stable dimer (PDB:6WJI). That the C-terminal domain has also been found to bind RNA (154) points to the critical role of this domain in the overall helical packaging of the viral genome (155). We targeted the dimerization interface of the CTD by removing one monomer from the crystallized dimer structure (Screen ID: 44) ( Supplementary Fig. 19 ), and also screened the dimerization interface via a blind docking procedure against the entire dimer surface (screen ID: 45) (Fig. 25) . The goal of these screens was to identify a small molecule that will bind to the monomer at the dimer interface and disrupt the formation of the nucleocapsid. However, the structure of the monomer alone has not been solved and given the extent of the interaction at the dimer interface, we anticipate considerable dynamics in the monomer. Therefore the structure extracted from the dimer may not adequately describe the monomer structure yielding imperfect hits. The other challenge of this target is that each virion has~65 spike trimers and with a ratio of S trimer to N of 1:4 (156, 157), this amounts to~260 monomers or~130 dimer interfaces. The abundance of contacts that would need to be disrupted means that a higher concentration of the inhibitor would be required for efficacy.

We screened against 17 proteins, 15 proteins of SARS-CoV-2 and two human proteins, targeting a total of 40 sites across these proteins with approximately 1.1 billion molecules per site. Due to the unprecedented global situation, we wanted to make the screening results available to researchers as soon as possible. The top 100 filtered hits as ranked by the docking score for each target site can be seen in Fig.  21 . The top 1000 hits per virtual screen, along with additional information such as the docking scores, molecular properties, and docking poses, can be found online at https://vf4covid19.hms.harvard.edu/. In addition, the top million hits for each target site are available for download from the same website in DataWarrior format.

As discussed earlier, not all the functional surfaces that were targeted had similar potential to accommodate a small molecule. The targeted site that yielded the weakest virtual hit compounds is the first (site 1) of the two targeted sites located on the spike interaction interface of ACE2. The reason for the relatively weak predicted binding affinities of the top scoring compounds is the flat and polar nature of this target site, which makes it very challenging for small molecules to bind sufficiently well to disrupt the interaction with the spike protein. The target yielding the virtual hits with the highest predicted binding affinities is the active site of the ExoN domain of nsp14. The high affinities are a product of the remarkably deep, buried pocket of this active site and the relatively high number of hydrophobic sites within that pocket. If we consider the top 1000 filtered hits, the weakest screen (ACE2, Screen ID: 2) had a mean docking score of -7.6 kcal/mol (2.3 µM) while nsp14 (Screen ID: 37) had the best mean docking score of -12.9 kcal/mol (0.3 nM). Although the trend was the same, the mean docking scores were better for the top 100 hits: -8.2 kcal/mol (1.1 µM) for ACE2 (Screen ID: 2) and -13.4 kcal/mol (0.14 nM) for nsp14 (Screen ID: 37) . Finally, as expected, the mean docking scores were even better for the top 10 hits: -8.52 kcal/mol (0.5 µM) for ACE2 (Screen ID: 2) and -14 kcal/mol (0.03 nM) for nsp14 (Screen ID: 37). The mean docking scores of the top 1000, 100, and 10 hits for each screen are shown in Fig. 21 . Out of the 45 virtual screens, 41 had a mean docking score for the top 1000 compounds higher than -8.2 kcal/mol. These scores indicate that sub-micromolar binders should be identifiable from the hits for each target site. The hits derived from the rigid-docking procedures described here could be further improved for potency by a second-stage screen, in which the target proteins can be allowed to be flexible. This can be achieved either by ensemble docking or allowing flexible side chains. Another way of improving the docking results in second stage screenings consists of using alternative docking programs, such as AutoDock Vina, Smina or Gnina (40, 158, 159) . For special types of ligands such as compounds containing carbohydrates or halogens, specialized docking programs such as VinaXB or Vina-Carb can be utilized to further increase the accuracy of the results (160, 161).

Small-molecule drug candidates that have been previously pre-approved by the FDA or other regulatory bodies for other indications, and those molecules that have been vetted for use in humans, including preclinical candidates, neutraceuticals, metabolites, and select natural products are particularly desirable hits in any inhibitor screen (162). This is because these compounds can be fast-tracked to clinical trials on the basis of previous data. Here we mined for such compounds in the top 1% of our hits from the "in stock" compounds of the ZINC library. We found 161 drugs (with 491 occurrences across all the screens) that are "world approved" in our top 1%. We further filtered these drug candidates to only those with a docking score better than -8 kcal/mol and show these 80 approved drugs along with their screening target and docking score in Supplementary Table 3 . Of these 80 drugs, 16 of them are currently being considered in clinical trials for COVID-19. The complete list of "world approved" hits along with their binding targets and docking score is available at https://vf4covid19.hms.harvard.edu/ world-approved-drugs. Several hits from the "world approved" drugs are from the steroid family. Corticosteroids such as betamethasone, ciclesonid, flumetasone and meprednisone acetate are already being investigated as . For example, we identified betamethasone as binding to nsp14, the bifunctional enzyme that acts as a methyltransferase and an exoribonuclease. Betamethasone binds to the active site of the exoribonuclease of nsp 14 ( Supplementary Fig. 24 ). While the usefulness of corticosteroids is largely attributed to their anti-inflammatory effects in the host, these screening results suggest the possibility of additional mechanisms of action that involve viral proteins. Other steroid hormones in clinical trial such as estradiol or dutasteride also came up as hits in our screens.

Of the non-steroid approved drug hits, tyrosine kinase inhibitors occupy a significant fraction. Drugs such as imatinib (Glivec ® ) are being tested in clinical trials due to their in vitro efficacy against SARS-CoV and 167) ; however, their mode of action is not yet fully understood. In our screens, imatinib binds to two targets: i) nsp14, but this time at the active site of the methyltransferase, and ii) the RNA-binding interface of the helicase, nsp13.

Of the 3897 "investigational" drugs in the ZINC15 database, 137 were hits (500 occurrences) and of the 101378 "in-man" compounds, 401 were hits (1061 occurrences). A full list of these molecules, along with their respective target sites and docking scores is available at (https://vf4covid19.hms.harvard.edu/ investigational-drugs). Multiple occurrences of a hit molecule partly stem from the different docking scenarios that we used for the same target site. In addition, some of the compounds may be represented more than once in the list because of a different tautomeric, isomeric, or protonation state, any of which earns the molecule a unique ID in the ZINC database. Despite the abundance of approved hits, some of which are already involved in or related to drugs in clinical trials, experimental confirmation of the specificity of hits from our screen against SARS-CoV-2 proteins is still needed to determine an antiviral mechanism of action. As noted earlier, when testing these compounds in viral assays, one should bear in mind the nature of the targets and be cognizant of differential effects on viral viability versus viral virulence. Furthermore, correlating "pre-approved" hits from the virtual screens with patient data, particularly severity of infection and recovery time, through examination of patients' regular medication and supplement regimens could reveal if any hit positively correlates with either a milder disease course or a faster time to recovery When performing in silico screening, we generally choose a 3D surface on the target protein, referred to as the "docking box", and evaluate the energetics of a molecule bound to that chosen surface. The docking box is judiciously chosen to target a known functional domain, either an active site, an allosteric site, or a protein-protein interaction interface. In practice, the docking box is typically extended to accommodate secondary interactions with the small molecule, especially when competing with a substrate. However, occasionally this results in identifying a tight binder that does not harbour any inhibitory function. It is important to take into account this possibility during follow-up experiments and test for binding using a direct binding assay such as ITC, SPR, MST or NMR. In particular, NMR and X-Ray structures can provide detailed information on the binding site and how the small molecule engages the target. It is possible to functionalize these non-inhibitory binders with warheads to degrade the targeted protein by established methods, referred to as proteolysis-targeting chimeras (PROTACS) (168, 169) . However the effectiveness of these PROTACs will depend on the concentration, rate of turnover, and accessibility of the target viral proteins. a mean docking scores of -10.83 and -11.41 kcal/mol. Similarly, in the case of PL pro , the best previously described active site inhibitor (173) has a binding free energy of -7.2 kcal/mol, while the top 100 compounds from two of our VirtualFlow screens (Screen IDs: 12 and 15) have a mean binding scores of -8.90 and -10.02 kcal/mol respectively. 21. These energies, in principle, should result in inhibitors with affinities two orders of magnitude higher than that of the original inhibitor from Ghosh, et al.. Lee, et al. described a novel helicase inhibitor that can block both the dSDNA unwinding and ATP hydrolysis activities of the SARS-CoV helicase (181). Docking of this molecule to the SARS CoV-2 helicase gave a score of -7.9 kcal/mol. We also targeted the active site of the SARS-CoV-2 helicase (Screen ID: 33), in addition to its RNA binding interface, and that screen resulted in a top 100 hits with a mean docking sore of -10.22 kcal/mol. In addition, there have been multiple attempts to develop small molecule inhibitors that target the active site of the RdRp, considered a promising target, from both SARS-CoV and 177) . Docking of the best molecules from these previously published studies against the SARS-CoV-2 RdRp resulted in docking scores of -6.1 and -6.8 kcal/mol, while our screens (Screen IDs 28 and 29) resulted in compounds with mean docking scores of -11.12 and -9.72 kcal/mol, respectively, for the top 100 hits. In general, our multi-target screening strategy resulted in hits with significantly higher docking scores than previously described hits re-tested against SARS-CoV-2 targets. However, the improvements in binding still needs to be experimentally validated.

In addition, there have already been multiple attempts to employ virtual screening of varying library sizes to identify approved drugs as well as discover new molecules that can effectively inhibit SARS-CoV-2 viral infection (66, (184) (185) (186) (187) (188) (189) (190) (191) (192) , and more than one screen is focused solely on M pro (184, 187, 190, 191) . It is important to note that in the case of M pro , the conformational plasticity of the active site means that screening against a single conformation,as is done in these studies, may be less effective at identifying functional hits. One work of note is that by Ton, et al. 1.3 billion compounds from the ZINC 15 library were screened against M pro using a Deep Docking algorithm (188). While Deep Docking significantly accelerates the screening of ultra-large compound libraries, it relies heavily on the docking scores of a small random subset of compounds to eliminate a large chunk of the compounds early in the docking workflow, and this can be detrimental to finding an absolute docking score for individual compounds.

A recent mass-spectrometry-based study has identified several host proteins that interact with SARS-CoV-2 viral proteins, leading to the identification of multiple druggable host targets and a series of known modulating compounds for these targets that were then shown to have antiviral activity in cell-culture-based assays (193) . The efficacy of these already approved host-directed compounds lends support to the development of these drugs as therapeutic interventions for SARS-CoV-2 infection. Coincidentally, some of the compounds from this mass spectrometry study were also identi-fied as hits in our screens against diverse viral proteins. For example, 'Nafamostat', an approved anticoagulant identified in Gordon, et al. as having a possible impact on cell entry, was also identified in our screens as a hit with good scores against three viral proteins: ORF7a, PL pro , and nucleoprotein. This compound is already undergoing clinical trials for COVID-19 (Ref:NCT04352400, NCT04418128) . Similarly, 'progesterone', a common birth control drug that is also known to have anti-inflammatory properties was identified in the proteomics study as a ligand with antiviral activity that targets sigma-1 or sigma-2 receptors. In our screens, this compound was identified as an inhibitor for nsp16, nsp7 and spike. Progesterone is also in clinical trials for treatment of COVID-19 (NCT04365127). Silmitasertib (CX-4945), an inhibitor of casein kinase II (CK2), was identified both in the proteomics study as well as in another recent study that mapped the host phosphorylation landscape in the context of SARS-CoV-2 infection (193, 194) . Silmitasertib was originally developed to be used in combination with chemotherapy. Here, we identify that Silmitasertib could potentially bind to nsp16. If some of these host-protein-targeted compounds can also directly inhibit some viral proteins, as suggested by the docking scores derived from our screens, this could form the basis for a unique regimen of multi-target drugs to treat COVID-19 that acts on both viral as well as host proteins simultaneously. A list of compounds that are common to both the interactome study and our virtual screens, along with their potential targets are provided in Supplementary Table 4 .

Our ultra-large library size and the multi-pronged screening approach is not only unprecedented in terms of scale, significantly enhancing the chances of finding an effective antiviral, but also provides a pool of potential antiviral compounds that could be developed further as pan-coronavirus drugs as well as combination therapies. Combination regimens of reverse transcriptase inhibitors and protease inhibitors have been found to be effective as anti-retroviral therapy for human immunodeficiency virus (HIV) and has lead to dramatic improvement in HIV infected patient health and survival worldwide (195) (196) (197) . Clinical studies have also shown that in case of severe influenza, a combination of multiple antiviral drugs is much more effective than a single one (198, 199) . Therefore, it could also be beneficial to develop a combination therapy to treat severely affected COVID-19 patients. Considering that the success or efficacy of any future SARS-CoV-2 vaccines is still unknown, combination therapeutic strategies for the control and treatment of coronavirus infections should be developed in parallel. The mutating nature of coronaviruses and the potential for the emergence of novel coronaviruses in the future make the development of broad spectrum antivirals desirable. For a protein to qualify as a candidate target for pan-coronavirus drug development, it should be i) critical for the viral replication or virulence, and ii) highly conserved across all known CoVs and likely to be conserved in emerging CoVs. While the structural proteins (S, N, M and E) are not as well conserved, the accessory proteins are conserved to an even lesser ex-tent across different CoV species (ProViz, (200) ). Highly conserved nonstructural proteins and conserved host proteins would therefore be ideal targets for the development of broad spectrum CoV drugs (201). While studies (202) have suggested that the S and N genes of SARS-CoV-2 are undergoing episodic selection during human transmission, recent analyses of genome samples from across the world suggest that the greatest genetic diversity is occurring in S, ORF3a and ORF8 (203) . Structural genomic analysis across multiple virus classes, including SARS-CoV-2, have shown that intra-viral interactions are more conserved than viral hostinteractions (204) (205) (206) (207) . The protein-protein interaction interfaces involved in the heteromeric RNA polymerase complex (composed of nsp7,nsp8 and nsp12) are evolutionarily conserved (204) and our top hits against these crucial PPIs represent promising candidates for the development of pancoronavirus inhibitors. Similarly, structural genomic analysis of the methyl transferase complexes (nsp10-nsp14 and nsp10-nsp16) also reveals PPIs that are fully conserved and with mutations limited to the the surface (204). Moreover, the substrate binding regions we used for PL pro , M pro , nsp14, nsp16 and the RNA binding site of the nucleocapsid protein have all been shown to be highly conserved (207), and the derived small molecules could also potentially be developed as pan-coronavirus therapeutics. Since most human coronaviruses differ in their use of host cell receptors and priming proteases (19), identifying a cell-based assay or functional animal model for developing pan-coronavirus therapeutics could be challenging. The use of normal human bronchial epithelia (NHBE) cells as a potential universal screening platform for multiple classes of coronaviruses is promising (208-210), and the general need for high-throughput ex vivo testing models will hopefully drive development in this area.

The work described here is only the first step in the drug discovery process. Virtual screening seeks to use structure and modelling-guided approaches to identify higher quality starting hits. Hits from these screens still need to be experimentally validated for binding, inhibition, and activity in the context of viral infection. Some of these targets, which affect viral immune evasion rather than replication, may need more complex evaluation in cell culture or in animal models to determine efficacy. While our own experimental validation of hits from these screens has begun, we believe that making these results available to a broader audience for experimentation is important in light of the current pandemic.

The alarming global spread of SARS-CoV-2 and the dearth of effective prophylaxis or treatment methods has resulted in a pressing need for accelerated drug discovery. Here we make use of the recent chemical space revolution that resulted in ultra-large make-on-demand libraries, to prioritize lead molecules and minimize the transition time from discovery to clinic. We have used the available-to-date SARS-CoV-2 structome to carry out detailed structure-based virtual screening against 17 different target proteins, frequently at multiple target sites, by leveraging the versatility of our re-cently developed in silico screening platform, VirtualFlow. The set of small molecule hits that we present here can aid drug development happening at multiple institutions worldwide, and the set of prospective drug molecules derived from this ultra-large multi-target screening campaign will potentially contribute to the building of a future arsenal of anticoronaviral drugs, ready to tackle future outbreaks. Fig. 4 . The ACE2 receptor (open conformation) and an example compound from the top 0.0001% of screened compounds bound near the spike interaction interface. a, The target protein ACE2 (gold) in a closed conformation bound to the RBD of the spike protein (magenta) and an example compound (light pink) from the virtual screen bound to target site 4 (around Leu39), which represents a dynamic pocket adjacent to the RBD binding interface (Screen ID:5). b, Electrostatic surface of the target protein (ACE2) bound to the RBD domain of the spike protein (magenta) and an example compound (light pink). c, An overview of the interactions between the ligand and the receptor structure. d, Residues within 4 Å of the ligand. e, Distribution of the docking scores of the top 100 virtual screening hits. Fig. 5 . M pro and an example compound from the top 0.0001% of screened compounds bound at the enzymatic active site a, M pro (violet) and an example compound (light pink) from the virtual screen bound to the active site. Here, a modified version of the structure wth PDB ID 6m0k was used (details are described in the main text)(Screen ID: 17). b, Electrostatic surface of the target protein to which an example compound (light pink) is bound. c, An overview of the interactions between the inhibitor and the protease structure. d, Residues within 4 Å of the inhibitor. e, Distribution of the docking scores of the top 100 virtual screening hits. Fig. 8. nsp9 and an example compound from the top 0.0001% of screened compounds bound at the dimerization interface (site 1). a, nsp9 dimer (one monomer in violet, one monomer in gold), where an example compound (light pink) from the virtual screen is bound to the dimerization interface (site 1) of the nsp9 monomer in violet(Screen ID:23). b, Electrostatic surface of the target protein to which an example compound (light pink) is bound. c, An overview of the interactions between the inhibitor and the nsp9 structure. d, Residues within 4 Å of the inhibitor. e, Distribution of the docking scores of the top 100 virtual screening hits. Supplementary Table 8 . Virtual screening hits 101 to 200 of the screen against the active site of M pro in which a modified structure based on the structure with PDB ID 6m0k was used (Screen ID: 17). The modifications are described in the main text. Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('as' for active site, 2 for docking scenario 2 of this target site). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. Supplementary Table 11 . Virtual hits 101 to 200 of the screen against ACE2 at the Spike interaction site in which the structure with PDB ID 6M18 was used (Screen ID: 2). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('spike' for spike interaction site, 2 for docking scenario 2). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. Top 100 virtual hits of the screen against ACE2 at a site adjacent to the Spike interaction interface (Screen ID: 5). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('spike' for spike interaction site, 5 for docking scenario 5). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. Supplementary Table 19 . Top 100 virtual hits of the screen against the active site of the macrodomain in closed conformation (Screen ID: 10). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('as' for active site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. to 200 of the screen against the active site of the macrodomain in closed conformation (Screen ID: 10). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('as' for active site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. . Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('as' for active site, 2 for docking scenario 2). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. (c1) . Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('as' for active site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. . Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('rna' for RNA binding site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. . Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('rna' for RNA binding site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. (c1) . Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('rna' for RNA binding site, 2 for docking scenario 2). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. Top 100 virtual hits of the screen against the nsp7 binding site of nsp12 (Screen ID: 32). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('nsp7' for nsp7 binding site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. Supplementary Table 60 . Virtual screening hits 101 to 200 of the screen against the nsp7 binding site of nsp12 (Screen ID: 32). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('nsp7' for nps7 binding site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. Top 100 virtual hits of the screen against the nsp7 binding site of nsp12 (Screen ID: 32). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('nsp7' for nsp7 binding site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. Supplementary Table 78 . Virtual screening hits 101 to 200 of the screen against the nsp10 binding site of nsp16 (Screen ID: 40). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('nsp10' for nsp10 binding site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. Top 100 virtual hits of the screen against the surface of ORF7a (Screen ID: 9). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('ppi' for protein-protein interface, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. Top 100 virtual hits of the screen against the oligomerization interface of the NTD of the nucleoprotein (Screen ID: 43). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('ppi' for protein-protein interface, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. Supplementary Table 84 . Virtual screening hits 101 to 200 of the screen against the oligomerization interface of the NTD of the nucleoprotein (Screen ID: 43). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('ppi' for protein-protein interface, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. . Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('ace2' for ACE2 binding site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. . Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('ace2' for ACE2 binding site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. Top 100 virtual hits of the screen against the active site of TMPRSS2 (Screen ID: 6). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('as' for active site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms.

C(F)(F)F)c4)no3)

C(F)(F)F)c4)no3)

C(=O)N1c1ccc(-c3ccccc3)cc1)C1c3ccccc3C2([N+](=O)[O-])c2ccccc21 vN

F)F)nc2ccccc12)

(=O)N3CCC(c4nc(-c5ccccn5)no4)CC3)C2)c1 vN-rna1-116

REAL C[C@H]1CCc2[nH]c3ccc(C(=O)N4CCC(C(=O)c5ccc6c(c5)NC(=O)[C@@H](C)O6)CC4)cc3c2C1 vN

REAL Cc1c(C(=O)Nc2ccccc2-c2nc(-c3ccccc3)n[nH]2)nnn1-c1ccc2ncccc2c1 vN-rna1-127

REAL Cc1cc2oc(=O)cc(CN3C(=O)N[C@](C)(c4cccc5ccccc45)C3=O)c2cc1C vN

CN3C(=O)N[C@@]4(CCOc5ccccc54)C3=O)cc(=O)oc2c1 vN

REAL Cn1ncc2c(=O)[nH]c(NN=C3CCC(N4C(=O)c5ccccc5C4=O)CC3)nc21 vN

REAL Cc1ccc(C)c(N2C(=O)c3ccc(-c4nc(-c5ccc6cc[nH]c6n5)no4)cc3C2=O)c1 vN

REAL CC(=O)N1Cc2ccccc2C[C@@H]1c1nc(-c2cccc(Cn3cnc4ccccc43)c2)no1 vN

REAL Cc1ccc(C)c(N2C(=O)c3ccc(-c4nc(-c5nccc6[nH]ccc56)no4)cc3C2=O)c1 vN

=O)n1C)c1cccc(-n2ccnn2)c1

REAL Cc1cc(-c2noc(CN3C(=O)c4ccccc4N4C(=O)CC[C@@]34C)n2)nc2ccccc12 vN

REAL NC(=O)[C@@H]1Cc2ccccc2CN1C(=O)c1ccc2c(c1)S(=O)(=O)c1ccccc1C2=O vN

c2ccc3c(c2)CCC3)NC(=O)N(Cc2cc(=O)oc3cc4c(cc23)CCC4)

C(=O)NNC(=O)c2ccc3c(c2)S(=O)(=O)c2ccccc2C3=O)c(C)n1-c1ccccc1 vN-rna1-164 Z383456236 -10.0 0.263 8.00 REAL Cc1cc(N2CCN(C(=O)c3cc(-c4cccc5ccccc45)nc4ccccc34)CC2)n2ncnc2n1 vN

C@@H]2Cc3ccccc3O2)c1 vN

00 REAL CN1C(=O)c2ccc(NC(=O)CN3C(=O)N[C@](C)(c4cccc5ccccc45)C3=O)cc2C1=O vN

Nc1nnc(-c2ccccn2)s1)

00 ZINC O=C1C(/C=C/c2ccc(Cl)cc2)=NN[C@H]2N1N=C1N=C(O)C3(NN12)c1ccccc1-c1ccccc13 vN-rna1-179

(=O)C(/C=C

 Supplementary Table 80 . Virtual screening hits 101 to 200 of the screen against the surface of ORF7a (Screen ID: 9). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('ppi' for protein-protein interface, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms.

C. Gorgulla | VirtualFlow@COVID-19 . Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('rna' for RNA binding site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms.

Top 100 virtual hits of the screen against the dimerization interface of the CTD of the nucleoprotein (Screen ID: 44). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('ctd' for CTD binding interface, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms.

Top 100 virtual hits of the screen against the oligomerization interface of the CTD of the nucleoprotein (Screen ID: 45). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('ctd' for CTD binding interface, 2 for docking scenario 2). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms.Supplementary Table 88 . Virtual screening hits 101 to 200 of the screen against the oligomerization interface of the CTD of the nucleoprotein (Screen ID: 45). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('ctd' for CTD binding interface, 2 for docking scenario 2). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms.

Top 100 virtual hits of the screen against the HR2 binding interface of the HR1 domain of the spike protein (Screen ID: 8). Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('hr2' for HR2 binding site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms. . Compounds were filtered so that hits had MW < 600 dalton, cLogP < 6, number of hydrogen bond acceptors < 11, and no reactive functional groups. A few compounds unsuitable for drug discovery were removed by visual inspection. The name of each compound consists of the initial letter 'v' for virtual hit, followed by the target protein name and the target site ('as' for active site, 1 for docking scenario 1). The score is the docking score given by QuickVina 2 in kcal/mol. The ligand efficiency (LE) is computed as LE = -score/#NonH, where #NonH is the number of heavy (i.e. non hydrogen) atoms.